GSK Q1 Earnings Call Highlights

1 week ago 4

MarketBeat

Wed, April 29, 2026 astatine 7:37 AM CDT 9 min read

GSK logo

Key Points

Strong Q1 results: Sales roseate 5% to much than GBP 7.6 cardinal with halfway operating nett up 10% and EPS up 9%, driven by specialty medicines (+14%) and a grounds Shingrix 4th (over GBP 1 billion); full-year guidance was reiterated.
Long-acting HIV momentum: ViiV drove 10% HIV income maturation (Cabenuva +31%, Apretude +44%), with a three-times-yearly Cabenuva signifier III connected way for a 2028 motorboat and Apretude PrEP registrational information expected H2 2026 for a H1 2027 launch, portion programs targeting twice-yearly dosing purpose for end-2030 approvals.
Pipeline and BD progress: Positive signifier III results for hepatitis B campaigner bepirovirsen (PDUFA Oct. 26, precedence reappraisal successful China) and accelerated concern successful oncology ADCs, positive acquisitions (RAPT, HS235) and portfolio actions expected to trim nett indebtedness by astir $1.2 billion.
Interested successful GSK PLC Sponsored ADR? Here are 5 stocks we similar better.

3 Bargain-Cheap Small Caps Worth a Second Look

GSK (NYSE:GSK) reported what absorption described arsenic a “strong” commencement to 2026, posting first-quarter income maturation and reiterating full-year guidance portion highlighting momentum successful specialty medicines, vaccines, and its long-acting HIV franchise. Executives besides utilized the telephone to stress efforts to accelerate late-stage pipeline programs and to supply further item connected cardinal merchandise launches and upcoming objective milestones.

Quarterly show and guidance

Luke Miels said first-quarter income roseate 5% to “more than GBP 7.6 billion,” driven by specialty medicines maturation of 14% and higher vaccine sales, “particularly done beardown Shingrix sales.” Core operating nett accrued 10% and EPS was up 9%, portion currency procreation reached GBP 1.4 billion. The institution declared a quarterly dividend of GBP 0.17.

→ Pipelines and Automation: 2 Energy Plays Built for Any Oil Price

Merck: 4 No-Brainer Reasons to Buy This Dip

Julie Brown said gross borderline improved 110 ground points owed to premix benefits from specialty medicines and Shingrix. SG&A declined 2% arsenic reported, which she said was helped by affirmative IP settlements; connected an underlying basis, SG&A grew 2%. Operating nett maturation of 10% included ineligible settlements worthy “3 percent points,” she added. EPS maturation reflected higher taxation and concern expenses, partially offset by the stock buyback.

Brown besides confirmed GSK’s February full-year guidance and discussed phasing. She noted vaccines maturation successful Q1 benefited from U.S. stocking tied to the Shingrix pre-filled syringe, portion from Q2 the institution volition statesman to annualize publically funded programs successful Japan and definite EU countries. She said wide medicines maturation is expected to beryllium weighted to the 2nd half, and operating nett maturation is besides expected to beryllium predominantly second-half weighted fixed productivity benefits and comparisons that see the prior-year RSV IP colony successful Q2.

Read Entire Article